Equity Profile

PODD

Insulet Corporation

Health CareHealth Care Equipment$10.2B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insulet Corporation (PODD) is a healthcare company that specializes in developing and manufacturing insulin delivery systems for people with diabetes. With a market cap of $10 billion, Insulet is a key player in the health care equipment sector, focusing on innovative solutions that improve patient outcomes and quality of life.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's market demand and overall business health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1-2026, Insulet reported an EPS of $1.42, surpassing estimates by 24.78%. However, the stock fell 9.70% the following day, indicating mixed market reactions despite the earnings beat.

Management Promises & Guidance

Continued focus on innovation in insulin delivery systems.
Commitment to expanding market presence.
Efforts to improve operational efficiencies.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Insulet's upcoming earnings, especially after a strong performance last quarter. However, the market is also wary of potential revenue misses given the volatility in stock reactions.

Bull Case

If Insulet can demonstrate strong revenue growth and maintain or improve its EPS, it could solidify its leadership position and drive stock prices higher.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of declining market share, it could lead to significant downward pressure on the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth rate for the upcoming quarter?

Revenue growth will be a key indicator of market demand and the company's ability to capture market share in a competitive landscape.

How is Insulet addressing potential supply chain challenges?

Supply chain issues could impact production and delivery, affecting overall performance and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Insulet's ability to innovate and capture market share, especially given recent advancements in insulin delivery technology.

Supporting Evidence

Insulet's historical EPS beat rate of 75% suggests a strong track record of exceeding expectations.

The recent performance in the healthcare sector indicates a growing demand for innovative medical devices.

Options pricing indicates a significant expected move, suggesting that investors are anticipating volatility that may not align with consensus views.

Key Risk

If revenue growth exceeds 15%, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could indicate the company's ability to sustain growth in a competitive healthcare market.

Bull Confirmed If

Revenue growth of 15% or higher compared to the previous quarter would confirm a strong demand for Insulet's products.

Bear Confirmed If

Any revenue decline or stagnation could signal a loss of market share and lead to negative investor sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests a potential average move of +1.90% on the following day, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance from management.

Miss

A miss could lead to a decline of around -1.09% on average, reflecting disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any commentary on supply chain management and its impact on production.
3Insights into competitive positioning against other insulin delivery systems.
4Management's outlook on future revenue growth and market expansion.
5Details on customer feedback and satisfaction with existing products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's market demand and overall business health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1-2026, Insulet reported an EPS of $1.42, surpassing estimates by 24.78%. However, the stock fell 9.70% the following day, indicating mixed market reactions despite the earnings beat.

Management Promises & Guidance

Continued focus on innovation in insulin delivery systems.
Commitment to expanding market presence.
Efforts to improve operational efficiencies.

Expectations

Wall Street Expectations

Bull Case

If Insulet can demonstrate strong revenue growth and maintain or improve its EPS, it could solidify its leadership position and drive stock prices higher.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of declining market share, it could lead to significant downward pressure on the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth rate for the upcoming quarter?

Revenue growth will be a key indicator of market demand and the company's ability to capture market share in a competitive landscape.

How is Insulet addressing potential supply chain challenges?

Supply chain issues could impact production and delivery, affecting overall performance and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Insulet's ability to innovate and capture market share, especially given recent advancements in insulin delivery technology.

Supporting Evidence

Insulet's historical EPS beat rate of 75% suggests a strong track record of exceeding expectations.

The recent performance in the healthcare sector indicates a growing demand for innovative medical devices.

Options pricing indicates a significant expected move, suggesting that investors are anticipating volatility that may not align with consensus views.

Key Risk

If revenue growth exceeds 15%, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it could indicate the company's ability to sustain growth in a competitive healthcare market.

Bull Confirmed If

Revenue growth of 15% or higher compared to the previous quarter would confirm a strong demand for Insulet's products.

Bear Confirmed If

Any revenue decline or stagnation could signal a loss of market share and lead to negative investor sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests a potential average move of +1.90% on the following day, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance from management.

Miss

A miss could lead to a decline of around -1.09% on average, reflecting disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any commentary on supply chain management and its impact on production.
3Insights into competitive positioning against other insulin delivery systems.
4Management's outlook on future revenue growth and market expansion.
5Details on customer feedback and satisfaction with existing products.